Bristol Myers says FDA updates Camzyos label to simplify treatment

Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. 'In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clinical and real-world data and more than 15,000 patients prescribed Camzyos in the U.S., this medicine has redefined the treatment landscape for symptomatic obstructive HCM and can have a significant impact for patients living with the condition. Simplifying treatment by reducing the frequency of echo monitoring not only improves the patient experience, but will also save time for cardiologists, allowing them to treat more patients,' said Al Reba, senior vice president, Cardiovascular & Immunology Commercialization at Bristol Myers Squibb.
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on BMY:
Disclaimer & DisclosureReport an Issue
Bristol Myers price target lowered to $58 from $63 at BofA
Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures
Cytokinetics price target lowered to $54 from $62 at BofA
Bristol-Myers Squibb: Hold Rating Amidst Trial Setbacks and Pipeline Challenges
Sell Rating for Bristol-Myers Squibb Due to Camzyos Trial Failure and Revenue Pressures

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

17 hours ago

• Yahoo

BofA Raises PT on Adobe (ADBE) Stock, Maintains Buy

Adobe Inc. (NASDAQ:ADBE) is one of the 10 software stocks analysts are upgrading. On June 13, BofA analyst Brad Sills upped the company's price objective to $475 from $424, while maintaining a 'Buy' rating, as reported by The Fly. As per the firm, Adobe Inc. (NASDAQ:ADBE)'s Q2 2025 results and outlook exhibit strong execution amidst a sluggish software demand backdrop, while its AI optionality remains intact. The firm's analyst hinted at a more resilient and diversified business, as well as healthy execution on growth initiatives. A team of engineers and scientists collaborating at a workstation surrounded by their applications and solutions. For FY 2025, the company targets total Adobe revenue of between $23.50 billion – $23.60 billion, and digital media segment revenue of between $17.45 billion – $17.50 billion. In Q2 2025, Adobe Inc. (NASDAQ:ADBE)'s digital media segment revenue came in at $4.35 billion, representing 11% YoY growth, or 12% in constant currency. Digital Media ARR, while exiting the quarter, came in at $18.09 billion, reflecting 12.1% growth YoY. While Adobe Inc. (NASDAQ:ADBE)'s AI-influenced ARR continues to contribute, the company's AI book of business from AI-first products like Acrobat AI Assistant, Firefly App and Services, and GenStudio for Performance Marketing has been tracking ahead of the $250 million ending ARR target by FY 2025 end. Adobe Inc. (NASDAQ:ADBE) is engaged in developing and selling creative, document, design, and marketing software. Aristotle Capital Management, LLC, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Adobe Inc. (NASDAQ:ADBE), the leading provider of content creation and publishing software, was a notable detractor during the quarter. This came despite the company reporting record revenue of over $5.7 billion in the first quarter—a 10% year-over-year increase, with double-digit increases across both its Digital Media and Digital Experience segments. The disconnect between strong fundamentals and share price weakness reflects ongoing market concerns around intensifying competitive threats from generative AI and lower-cost design platforms. Market sentiment has remained cautious around the perceived disruption risk posed by new AI-driven entrants, including OpenAI's Sora for video generation and platforms like Canva, which cater to the broader prosumer and small and medium-sized business segment. However, we continue to view these as largely non-overlapping with Adobe's core base of creative professionals, enterprises and agencies—audiences that demand precision, control and integration within larger workflows. Canva, while expanding its feature set, remains limited in its enterprise readiness and depth. Sora, meanwhile, remains early-stage and experimental, with limited commercial application at this point. Crucially, Adobe is not standing still. The company is actively embedding generative AI across its ecosystem through Firefly, which is commercially safe (i.e., free of copyrighted sources to train its models) and integrated natively into Creative Cloud applications like Photoshop and Illustrator. Firefly has shown strong early traction, generating $125 million in annualized recurring revenue, with management expecting that figure to double by year end. While modest in size relative to Adobe's total revenue, Firefly's monetization strategy is still in its early innings, with further potential through upselling, usage-based pricing and expanded use cases. Beyond monetization, AI integration enhances Adobe's long-term competitive moat through product functionality, stronger customer engagement and increased switching costs. Adobe's unique access to proprietary data, content workflows and creative content allows it to fine-tune models that serve the high-end needs of professionals—capabilities that generic AI models lack. Strategic partnerships with Microsoft (e.g., Firefly in Microsoft 365 Copilot) and ongoing momentum in Adobe Express further extend its reach into new user segments. Ultimately, we believe Adobe has a durable competitive advantage, underpinned by a large installed base, subscription-led business model, strong brand equity and a long track record of innovation. While short-term concerns over AI disruption have weighed on the stock price, we believe Adobe is well-positioned to harness AI as a driver of value rather than being displaced by it.' While we acknowledge the potential of ADBE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADBE and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.

Yahoo

a day ago

• Yahoo

BofA Trimmed Lululemon Target to $370, Should Have Lowered the Buy Rating

BofA Securities has lowered its price target on Lululemon (NASDAQ: LULU) from $400 to $370 while maintaining a Buy rating a couple of weeks ago. The revision followed updated guidance from the company, which kept its fiscal 2025 sales forecast intact but trimmed its earnings outlook by 2.5%. The new EPS range stands at $14.58 to $14.78. The adjustment was supposed to show expected pressure from tariffs and a slightly more promotional retail landscape. Tariffs are forecast to reduce margins by 40 basis points this fiscal year, with a sharper 60 basis point hit expected in Q2. Mitigation efforts are slated to start in the second half. Despite the earnings revision, BofA remained upbeat on the company's broader trajectory. Sales plans are reportedly on pace, and early product launches have shown promise, with more scale expected in the coming months. Management also plans targeted price hikes and sourcing improvements to protect margins. LULU shares lost 30% of their value since BofA's call and currently trade at a trailing P/E of 15. While we acknowledge the potential of LULU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

2 days ago

• Yahoo

Caris Life Sciences indicated to open at $30, IPO priced at $21 per share

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris describes itself as a 'patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare.' Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to 'analyze and further unravel the molecular complexity of disease' through comprehensive molecular profiling and the application of advanced AI and machine learning algorithms at scale, the company states. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data